companydata.dkcompanydata.dk

ORIFARM GENERICS HOLDING A/S: Financial statements 2015

CVR: 27347223

Source: annual report 2015, Danish Business Authority

01/01/2015 – 31/12/2015

ORIFARM GENERICS HOLDING A/S (CVR 27347223) has filed annual accounts for 2015. In 2015, the company reported a gross profit of DKK 5,654,000 and a net result of DKK 5,160,000 compared with DKK 4,116,000 the year before. That is a decrease of 31.3% compared with the year before. Equity in the 2015 report amounted to DKK 194,332,000. The solvency ratio was 39.5%.

Gross Profit
DKK 5,654,000
Profit/Loss
DKK 5,160,000
Equity
DKK 194,332,000
Total Assets
DKK 492,026,000

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2015-5.7M5.2M194.3M-
2014-8.2M4.1M15.3M-
2013-6.8M-150K11.5M-
2012-13.1M7.1M12M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is ORIFARM GENERICS HOLDING A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2015

Claus Christian Bayer joins the board of ORIFARM GENERICS HOLDING A/SAug 26, 2015

As of August 26, 2015, Claus Christian Bayer has joined the board of directors of ORIFARM GENERICS HOLDING A/S.

Rolf Eckersberg joins the board of ORIFARM GENERICS HOLDING A/SAug 26, 2015

As of August 26, 2015, Rolf Eckersberg has joined the board of directors of ORIFARM GENERICS HOLDING A/S.

ORIFARM GENERICS HOLDING A/S: The 2014 annual report is outMay 29, 2015

ORIFARM GENERICS HOLDING A/S has published its annual report for 2014. Gross profit came to DKK 8,233,000, and the net result was DKK 4,116,000.

About ORIFARM GENERICS HOLDING A/S

ORIFARM GENERICS HOLDING A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2003. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named COPYFARM HOLDING A/S. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GROUP A/S. The company has 0 employees (2016). In 2025, the company reported revenue of DKK 459,463,000 and a net result of DKK 273,125,000 compared with DKK 89,363,000 the year before. Equity in the 2025 report amounted to DKK 2,399,752,000.

Source: annual report 2025, Danish Business Authority